Carvedilol prevents severe hypertensive cardiomyopathy and remodeling

Journal of Hypertension

Volumn 16, Issue 6, 1998, Pages 871-884

  Barone, Frank C ^a,d   Campbell Jr , Wallace G ^b,c   Nelson, Allen H ^a   Feuerstein, Giora Z ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UW2521 ^*  (United States)

Author keywords

Blood pressure; Cardiac hypertrophy; Cardiac remodeling; Cardiomyopathy; Cardioprotection; Carvedilol; Congestive heart failure; Heart rate; Stroke prone spontaneously hypertensive rats

Indexed keywords

CARVEDILOL;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; FAT INTAKE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART PROTECTION; HEART SIZE; HISTOPATHOLOGY; HYPERTENSION; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0031836038     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816060-00019     Document Type: Article

References (67)

1. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38 (suppl): 82-88.
2. Ruffolo RR Jr, Boyle DA, Venuti RP, Lucas MA. Carvedilol (Kredex): a novel, multiple action cardiovascular agent. Drugs Today 1991; 27:465-492.
3. Feuerstein GZ, Poste G, Ruffolo RR. Carvedilol update III: rationale for use in congestive heart failure. Drugs Today 1995; 31:307-326.
4. Ma XL, Yue T-L, Lopez BL, Barone FC, Christopher TA, Ruffolo RR, et al. Carvedilol, a new beta adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996; 277:128-136.
5. Ma XL, Lopez BL, Lui GL, Christopher TA, Gao F, Guo Y, et al. Hypercholestrolemia impairs a detoxification mechanism against peroxinitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 1997; 80:894-901.
6. Yue T-L, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263:92-98.
7. Yue T-L, Feuerstein GZ. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, inhibits oxygen radical mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992; 1:27-35.
8. Yue T-L, Lysko PG, Barone FC, Ruffolo RR, Feuerstein GZ. Carvedilol, a new antihypertensive drug with unique antioxidant activity; potential role in cerebroprotection. NY Acad Sci 1995; 738:230-242.
9. Yue T-L, McKenna PJ, Cheng HY. Carvedilol, a new antihypertensive agent, prevents oxidative injury to endothelial cells. Hypertension 1993; 22:922-928.
10. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94:2807-2816.
11. Colucci WS, Packer M, Bristow MR, Gilbert EM, Conn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94:2800-2806.
12. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94:2817-2825.
13. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, et al. Double blind, placebo controlled study of the long-term efficacy of carvedilol in patients with severe heart failure. Circulation 1995; 92:1499-1506.
14. Marco M, Nardi M, Giubbini R, DeiCas L. Effects of short- and long term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated hypertrophy. J Am Coll Cardiol 1994; 24:1678-1687.
15. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995; 25:1225-1231.
16. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. W Engl J Med 1996; 334:1349-1355.
17. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure; the precise trial. Circulation 1996; 94:2793-2799.
18. Ohlstein EH, Vickery L, Arleth A, Cyronak M, Barone FC, Sung CP, et al. Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 1994; 16:163-177.
19. Ohlstein EH, Douglas SA, Sung C-P, Yue T-L, Louden C, Arleth A, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 90:6189-6193.
20. Barone FC, Nelson AH, Ohlstein EO, Willette RN, Sealey JE, Laragh JH, et al. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Phamacol Exp Ther 1996; 279: 948-955.
21. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 1974; 34/35 (suppl 1): 143-153.
22. Ogiku N, Sumikawa H, Hashimoto Y, Ishida R. Prophylactic effect of imidapril on stroke in stroke-prone spontaneously hypertensive rats. Stroke 1993; 24:245-252.
23. Luna LG. Manual of histologie staining methods of the Armed Forces Institute of Pathology, New York: McGraw-Hill; 1968.
24. + feeding in stroke-prone hypertensive rats. Hypertension 1990; 15:318-326.
25. Carmargo MJF, von Lutterotti N, Campbell WG Jr, Pecker MS, James GD, Timmerman PBMWM, et al. Control of blood pressure and end organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993; 11:31-40.
26. Siegal S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956.
27. Winer BJ. Statistical principles in experimental design. New York: McGraw-Hill; 1971.
28. Nagoaka A, Iwatsuka H, Sozuski Z, Okamoto K. Genetic predisposition to stroke in spontaneously hypertensive rats. Am J Physiol 1976; 230:1354-1359.
29. Yamori Y, Horie R, Handa H, Sato M, Fukase M. Pathogenic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 1976; 7:46-53.
30. Yamori Y, Nagaoka A, Okamoto K. Importance of genetic factors in stroke: an evidence obtained by selective breeding of stroke-prone and resistant SHR. Jpn Circ J 1974; 38:1095-1100.
31. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in heart failure. Circulation 1996; 94:2285-2296.
32. Frolich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol 1979; 44:959-963.
33. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S. et al. Relation of left ventricular load and contractile performance to left ventricular mass in hypertension. Circulation 1990; 81:25-36.
34. De Simone G, Moccia D, Di Lorenzo L, Buonissimo S, Constantino G, de Divitiis O. Echocardiographic assessment of arterial impedance: relationship to anatomic left ventricular patterns in systemic hypertension. Am J Noninvasive Cardiol 1988; 2:232-237.
35. Gordon AL, Inchiosa MA, Lehr D. Isoproterenol-induced cardiomegaly: assessment of myocardial protein content, actomysin ATPase and heart rate. J Mol Cell Cardiol 1972; 4:543-557.
36. Sen S, Tarazi RC, Bumpus FM. Cardiac effects of angiotensin antagonists in normotensive rats. Clin Sci Lond 1979; 56:439-443.
37. Friberg P, Ely DL, Wahlander H, Nilsson H, Folkow B. Cardiac design and pressure-volume characteristics of the left ventricle in normotensive (WKY) and hypertensive (SHR) rats after various dietary sodium treatments. Acta Physiol Scand 1986; 126:477-484.
38. Lindpainter K, Sen S. Role of sodium in hypertensive cardiac hypertrophy. Circ Res 1985; 57:610-617.
39. Sen S, Young DR. Role of sodium in modulation of myocardial hypertrophy in renal hypertensive rats. Hypertension 1986; 8:918-924.
40. De Simone G, Devereux RB, Camargo MJF, Wallerson DC, Laragh JH. Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension. Am J Physiol 1993; 33:H2103-H2110.
41. McPhillips JJ, Schwemer GT, Scott DI, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension: a dose response study. Drugs 1988; 36 (suppl 6):82-91.
42. Lompre AM, Schwartz K, D'Albis A, Lacombe G, Thiem NV, Swynghedauw B. Myosin isoenzyme redistribution in chronic heart failure. Nature 1979; 282:105-107.
43. Mercadier JJ, Lompre AM, Wisnewsky C, Samuel JL, Bercovici J, Swynghedauw B. et al. Myosin isoenzyme changes in several models of rat cardiac hypertrophy. Circ Res 1981; 49:525-532.
44. Gorza L, Mercadier JJ, Schwartz K, Thornell LE, Sartore S, Schiaffino S. Myosin types in the human heart. An immunofluorescence study of normal and hypertrophied atrial and ventricular myocardium. Circ Res 1984; 54:694-702.
45. Schwartz K, Lecarpentier Y, Martin JL, Lompre AM, Mercadier JJ, Swyngedauw B. Myosin isoenzyme distribution correlates with speed of myocardial contraction. J Mol Cardiol 1981; 13:1071-1075.
46. Cooper G. Cardiocyte adaptation to chronically altered load. Annu Rev Physiol 1987; 49:501-518.
47. Morgan HE, Gordon EE, Kira Y, Chua BHL, Russo LA, Peterson CJ, et al. Biochemical mechanisms of cardiac hypertrophy. Annu Rev Physiol 1987; 49:333-343.
48. Caulfield JB. Morphologic alterations of the collagen matrix with cardiac hypertrophy. Perspec Cardiovasc Res 1983; 7:167-175.
49. Contard F, Koteliansky V, Marotte F, Dubus I, Rappaport L, Samuel JL. Specific alterations in the distribution of extracellular matrix components within rat myocardium during the development of pressure overload. Lab Invest 1991; 64:65-75.
50. Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT. Reactive and reparative fibrillar collagen remodeling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res 1990; 24:741-747.
51. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989; 64:1041-1050.
52. Han OO, Mitsuoka T, Matsumoto Y, Ahmed R, Hirata M, Hirata T, et al. Arrhythmogenic properties of the ventricular myocardium in cardiomyopathic Syrian hamster. Cardiovasc Res 1991; 25:49-57.
53. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariety J, et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 1994; 70:286-294.
54. Engelmann GL, Vitullo JC, Gerrity RG. Morphometric analysis of cardiac hypertrophy during development, maturation, and senescence in spontaneously hypertensive rats. Circ Res 1987; 60:487-494.
55. Feuerstein G, Ruffolo RR, Yue T-L. Apoptosis and congestive heart failure. Trends Cardiovasc Med 1998; 7:249-255.
56. Greis J, Kretzschmar R, Neuman BW. Development of hypertension and life span in stroke prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs. J Cardiovasc Pharmacol 1989; 13 (suppl 4):S79-S82.
57. 2+ transport in sarcoplasmic reticulum. Cardiovasc Res 1984; 18:371-376.
58. Nagaoka A. Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats. J Hypertens 1986; 4 (suppl 3): S523-S525.
59. Stier CT, Benter IF, Ahmad S, Suo H, Selig N, Roethel S, et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 1989; 13:115-121.
60. Vacher E, Fornes P, Domerque V, Richer C, Bruneval P, Guidicelli JF. Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1993; 6:951-959.
61. Camargo MJF, von Lutterotti N, Pecker MS, James GD, Timmerman PBMWM, Laragh JH. DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed high sodium diet. Am J Hypertens 1991; 4:3415-3455.
62. Laragh JH, Baer L, Brunner HG, Buhler FR, Sealey JE, Vaughan ED. Renin, angiotensin and aldosterone System in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52:633-652.
63. Tobian L, Lange J, Ulm K, Wold L, Iwai J. Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered. Hypertension 1985; 7 (suppl 1):110-114.
64. Ishimitsu T, Tobian L. High potassium diets reduce endothelial permeability in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1996; 23:241-245.
65. Ishimitsu T, Tobian L, Sugimoto K, Everson T. High potassium diets reduce vascular and plasma lipid peroxides in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1996;18:659-673.
66. Brooks DP, Short BG, Cyronak MJ, Contino LC, DiCristo M, Wang Y-X, et al. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol 1993; 109:581-586.
67. Lysko PG, Lysko KA, Yue T-L, Webb CL, Gu JL, Feuerstein G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 1992: 23:1630-1636.